Spark Therapeutics (ONCE) Shares Down 0%

Spark Therapeutics Inc (NASDAQ:ONCE) shares traded down 0% on Tuesday . The stock traded as low as $50.06 and last traded at $50.23. 1,442,221 shares traded hands during trading, an increase of 87% from the average session volume of 772,221 shares. The stock had previously closed at $50.23.

Several research analysts recently weighed in on the company. Wedbush upgraded Spark Therapeutics from an “underperform” rating to a “neutral” rating and dropped their target price for the stock from $65.00 to $50.00 in a research note on Tuesday, December 12th. They noted that the move was a valuation call. Mizuho restated a “buy” rating and set a $79.00 target price on shares of Spark Therapeutics in a research note on Wednesday. BMO Capital Markets set a $64.00 target price on Spark Therapeutics and gave the stock a “buy” rating in a research note on Wednesday. Raymond James Financial set a $66.00 price target on Spark Therapeutics and gave the stock a “buy” rating in a research report on Wednesday. Finally, Stifel Nicolaus reaffirmed a “buy” rating and set a $64.00 price target (down previously from $73.00) on shares of Spark Therapeutics in a research report on Wednesday. Two investment analysts have rated the stock with a sell rating, five have assigned a hold rating and seventeen have issued a buy rating to the stock. The company currently has an average rating of “Buy” and an average target price of $69.88.

The stock has a market capitalization of $1,858.78, a price-to-earnings ratio of -6.64 and a beta of 3.02.

Spark Therapeutics (NASDAQ:ONCE) last released its quarterly earnings results on Tuesday, February 20th. The biotechnology company reported ($1.73) earnings per share for the quarter, hitting analysts’ consensus estimates of ($1.73). Spark Therapeutics had a negative return on equity of 65.56% and a negative net margin of 2,100.80%. The company had revenue of $7.41 million during the quarter, compared to analysts’ expectations of $9.53 million. equities analysts predict that Spark Therapeutics Inc will post -4.83 EPS for the current fiscal year.

In other Spark Therapeutics news, insider Katherine A. High sold 5,000 shares of the business’s stock in a transaction that occurred on Tuesday, November 28th. The stock was sold at an average price of $71.32, for a total transaction of $356,600.00. Following the completion of the sale, the insider now directly owns 215,000 shares in the company, valued at approximately $15,333,800. The transaction was disclosed in a document filed with the SEC, which is available through this link. 7.30% of the stock is currently owned by insiders.

Hedge funds have recently bought and sold shares of the company. Gilder Gagnon Howe & Co. LLC purchased a new position in Spark Therapeutics in the fourth quarter worth approximately $28,188,000. Orbimed Advisors LLC purchased a new position in Spark Therapeutics in the third quarter worth approximately $38,340,000. Rockefeller Financial Services Inc. grew its position in Spark Therapeutics by 27,905.0% in the fourth quarter. Rockefeller Financial Services Inc. now owns 353,983 shares of the biotechnology company’s stock worth $18,202,000 after acquiring an additional 352,719 shares during the period. Jennison Associates LLC purchased a new position in Spark Therapeutics in the third quarter worth approximately $27,239,000. Finally, JPMorgan Chase & Co. grew its position in Spark Therapeutics by 15.0% in the third quarter. JPMorgan Chase & Co. now owns 1,848,988 shares of the biotechnology company’s stock worth $164,986,000 after acquiring an additional 241,016 shares during the period.

ILLEGAL ACTIVITY NOTICE: This article was first reported by Week Herald and is the sole property of of Week Herald. If you are viewing this article on another website, it was stolen and reposted in violation of United States and international trademark and copyright laws. The correct version of this article can be accessed at https://weekherald.com/2018/02/22/spark-therapeutics-once-shares-down-0.html.

Spark Therapeutics Company Profile

Spark Therapeutics, Inc is a gene therapy company. The Company focuses on treating orphan diseases. It has a pipeline of product candidates targeting multiple rare blinding conditions, hematologic disorders and neurodegenerative diseases. Its pipeline includes a product candidate targeting choroideremia (CHM), which is in a Phase I/II clinical trial and a product candidate for hemophilia A, which is in a Phase I/II clinical trial.

Receive News & Ratings for Spark Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spark Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply